Osteoporosis Biosimilar OK’d; New Endo Guidelines; A Hot Spot for Stealing Ozempic
MedPage Today) — The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture and increasing bone mass in several patient populations, said maker Samsung Bioepis. A group of 5src…
MedPage Today) — The FDA approved the denosumab biosimilar Ospomyv, interchangeable with Prolia, for preventing osteoporosis-related fracture and increasing bone mass in several patient populations, said maker Samsung Bioepis.
A group of 5src…
Read More
About Author
